The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.